Chao et al. were the first to explore in vivo if antibodies against CD47 could be a potential treatment for malignancies; astonishingly, they found that blocking anti-CD47 antibodies preferentially enabled phagocytosis of non-Hodgkin lymphoma (NHL) cells and synergized with rituximab (anti-CD20 antibody). Here, CD47 is linked to non-Hodgkin lymphoma.